Semaglutide-driven visceral fat loss slowed epigenetic aging clocks in a 32-week trial
Louis highlights a FoundMyFitness note that in a 32-week semaglutide trial in adults with excess visceral fat, multiple epigenetic aging clocks showed improvement. The proposed mechanism is less adipose-driven inflammatory and metabolic signaling.



